Prescription medicine
Nerandomilast Brand names: Jascayd
Nerandomilast (Jascayd) is a prescription medicine with an FDA approval on record since 2025. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the nerandomilast FDA label on DailyMed (effective August 14, 2026, Boehringer Ingelheim Pharmaceuticals, Inc.); the NDA 218764 record on Drugs@FDA; every nerandomilast label on DailyMed.
Highlights of the record
FDA label of August 14, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageJASCAYD is a phosphodiesterase 4 (PDE4) inhibitor indicated for: The treatment of idiopathic pulmonary fibrosis in adult patients.
Forms and strengths
- 9 mg
- 18 mg
Film-coated tablet.
On the market
- Earliest approval on file
- October 7, 2025 Jascayd, Boehringer Ingelheim; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- October 22, 2038 Jascayd tablets; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 1,163 through July 30, 2026
What is nerandomilast used for?
From the label: indications and usageJASCAYD is a phosphodiesterase 4 (PDE4) inhibitor indicated for: The treatment of idiopathic pulmonary fibrosis in adult patients. ( 1.1 ) The treatment of progressive pulmonary fibrosis in adult patients. ( 1.2 ) 1.1 Idiopathic Pulmonary Fibrosis JASCAYD is indicated for the treatment of idiopathic pulmonary fibrosis (IPF) in adult patients. 1.2 Progressive Pulmonary Fibrosis JASCAYD is indicated for the treatment of progressive pulmonary fibrosis (PPF) in adult patients.
Source: FDA drug label (JASCAYD), Boehringer Ingelheim Pharmaceuticals, Inc., effective August 14, 2026 (SPL set fa1b14c6-957f-d326-5099-911bfe33e391), via openFDA; the full label on DailyMed
Is there a generic for nerandomilast (Jascayd)?
No generic nerandomilast is approved (Drugs@FDA, October 8, 2026).
The Orange Book lists 5 patents for Jascayd tablets: the compound patent runs to August 23, 2032, and the last listed entry to October 22, 2038. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2025 earliest approval on file
- 2038 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What does the nerandomilast label say about other medicines?
The nerandomilast label names 1 other medicine in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Pirfenidone | drug interactions | Pirfenidone Recommended dosage of JASCAYD is 18 mg twice daily when used concomitantly with pirfenidone. |
Source: FDA drug label (JASCAYD), Boehringer Ingelheim Pharmaceuticals, Inc., effective August 14, 2026 (SPL set fa1b14c6-957f-d326-5099-911bfe33e391), via openFDA; the full label on DailyMed
What do FAERS reports show for nerandomilast?
The FDA Adverse Event Reporting System holds 1,163 reports that list nerandomilast among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 92 are coded as a death and 193 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Nerandomilast side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other